#USA #Philadelphia #Generic Drugs #Lawsuit Settlement #Consumer Rights

Settlement Announcement: Your Right to Claim

On July 10, 2026, Fine, Kaplan and Black, R.P.C. officially announced a potentially significant development for many Americans who paid for specific prescription generic drugs between May 1, 2009, and December 31, 2019. Those individuals may be eligible to participate in a class action lawsuit settlement and submit claims for compensation.

This legal notice has been authorized by a federal court and is not a solicitation by lawyers. If you find yourself fitting this descriptive bracket, it’s crucial to understand the important details surrounding your eligibility and how you might obtain compensation.

Who Qualifies for Compensation?

Individuals who are part of what is known as catastrophic or end-payer prescription (EPP) class members may be entitled to file a claim. Specifically, if you lived in the U.S. (excluding Indiana and Ohio) and, at any time during the specified date range, either purchased or reimbursed funds for designated prescription generics—whether for yourself or family use (not for resale)—you could be included in one or more settlement groups.

The federal court has identified four distinct EPP settlement groups, each with specific eligibility criteria. Notably, certain entities are excluded from these groups, which makes it essential to review the complete descriptions available at the settlement website.

The Nature of the Lawsuit

The crux of the lawsuit revolves around allegations that generic drug manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law. The suit claims that these actions led to inflated costs for end payers, including consumers and third-party payers such as insurance companies and employers with co-pay prescription programs. While the defendants in the settlement have denied any wrongdoing, the legal proceedings continue against those who have not settled.

Settlement Details

Confirmed details declare that one of the primary defendants, Sandoz, has agreed to contribute a noteworthy settlement fund of $275 million. Meanwhile, Sun and Taro Pharmaceuticals have committed $200 million toward the settlement total. Other manufacturers, such as Heritage and Apotex, will also contribute to this settlement amount by paying specific sums for their involvement. All settlement defendants are expected to collaborate with EPP in lawsuits against unresolved defendants in the future.

After deducting fees related to the settlement notice, administration costs, and any other legal fees, eligible claimants will receive payments distributed from the remaining fund.

How to Submit Your Claim

To access your potential settlement, it is required to submit a claim form along with supporting documentation. You have several options: complete and submit an online claim on the EPP settlement website by November 9, 2026, or mail a hard copy of the claim form by the same deadline (based on postmark dates).

Anyone needing a hard copy of the claim form can visit the EPP settlement website or call the provided toll-free number. A valid claim will allow you to receive your proportionate share from the settlement funds, calculated based on the total eligible claims and the amount spent on designated prescription generics during the claim period.

Failure to submit your claim by the deadline means you forfeit any rights to compensation from this settlement. Given the considerable amount involved, it is beneficial for eligible individuals to act promptly and take the necessary steps to file a claim.

For more information, individuals can call 1-877-316-0171 or visit www.GenericDrugsEndPayerSettlement.com. It’s imperative that affected individuals don’t miss the opportunity to reclaim a portion of their expenditures through this remarkable settlement.